US President Donald Trump came into office vowing to reduce the cost of prescription drugs for the American consumer. But will that relief come at the expense of pharmaceutical balance sheets? We discuss the implications of US policy for pharma companies with Sam Fazeli of Bloomberg Intelligence.
Image Credit: Shutterstock.com

Rethinking Kevin Warsh & 3 Jackson Hole Signals to Watch
12:15

Trump’s Approval Drop: Midterm Risks & Gridlock
12:24

Am I Entitled to Selangor’s Sukma Public Holiday
08:24